First Wave BioPharma, Inc.

符号: FWBI

NASDAQ

2.82

USD

今天的市场价格

-0.2784
市盈率
0.0000
PEG比率
5.71M
MRK市值
0.00%
DIV收益率

First Wave BioPharma, Inc. (FWBI) 财务报表

Q: 什么是 First Wave BioPharma, Inc. (FWBI) 总资产是多少？

First Wave BioPharma, Inc. (FWBI) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 First Wave BioPharma, Inc. (FWBI). 的默认数据。公司收入显示 0 M 的平均值，即 0.000 % 增长率。整个期间的平均毛利润为 -0.247 M，即 0.182 %. 平均毛利率为 0.000 %. 公司去年的净收入增长率为 -0.047 %，等于 -0.258 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 First Wave BioPharma, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.265. 在流动资产领域，FWBI 的报告货币为4.956. 这些资产中的很大一部分，即 3.712 是现金和短期投资。与去年的数据相比，该部分的变化率为1.723%. 公司的长期投资虽然不是其重点，但以报告货币计算的0.022（如果有的话）为0.022。这表明与上一报告期相比，0.042% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 0.147. 这一数字表明，-0.064% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 3.603. 这方面的年同比变化率为 0.314%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为0，存货估值为 0，商誉估值为 1.68（如有. 无形资产总额（如果有）按 0 估值.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
balance-sheet.row.cash-and-short-term-investments	10.3	3.7	1.4	8.2	6.1	0.2	1.1	0.6	1.8	0.6	0.2
balance-sheet.row.short-term-investments	0	0	0	0	0	0	0	0	0	0.1	0.1
balance-sheet.row.net-receivables	0.02	0	0.1	0	0.6	2.6	3.2	1.1	1	1.1	0.4
balance-sheet.row.inventory	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-current-assets	4.49	1.2	2	1176268	1.3	0.6	0.5	0.3	0.2	0.4	0
balance-sheet.row.total-current-assets	14.82	5	3.4	9.4	7.9	3.4	4.8	2	3	2.1	0.7
balance-sheet.row.property-plant-equipment-net	0.98	0.2	0.3	0.4	0.1	0.2	0.1	0.1	0.2	0.2	0.2
balance-sheet.row.goodwill	6.74	1.7	1.7	1.9	2.1	1.9	1.9	2	1.8	1.8	2
balance-sheet.row.intangible-assets	0	0	0	0	2.9	3.4	0.6	1.3	1.8	2.6	3.6
balance-sheet.row.goodwill-and-intangible-assets	6.74	1.7	1.7	1.9	4.9	5.3	2.5	3.4	3.6	4.4	5.7
balance-sheet.row.long-term-investments	0.09	0	0	0	0	0	0	0	7.9	0	0
balance-sheet.row.tax-assets	-0.06	0	0	0	0	0	0	0	-7.9	0	0
balance-sheet.row.other-non-current-assets	0.12	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-non-current-assets	7.86	1.9	2	2.4	5.1	5.5	2.7	3.5	3.8	4.6	5.9
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	22.67	6.9	5.4	11.8	12.9	8.9	7.5	5.5	6.8	6.7	6.6
balance-sheet.row.account-payables	3.19	0.6	0.7	2.7	1.6	2.2	2.2	0.7	1.1	0.4	0.8
balance-sheet.row.short-term-debt	1.41	0.7	0.7	0.7	0.6	1.6	0.3	0.4	0.2	6.6	1.1
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	0.69	0.1	0.2	0.3	0	0	0	0	0	0	0
Deferred Revenue Non Current	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	2.58	0.8	1.1	8	13.4	0.5	0.5	1.4	1.1	0.8	0.1
balance-sheet.row.total-non-current-liabilities	0.69	0.1	0.2	7.3	0	0	2.5	1.3	1.2	1.5	1.5
balance-sheet.row.other-liabilities	0	0	0	0	0	0	-2.5	0	0	0	0
balance-sheet.row.capital-lease-obligations	0.89	0.1	0.3	0.4	0.1	0.1	0	0	0	0	0
balance-sheet.row.total-liab	12.2	3.3	2.7	19.6	15.6	4.3	3	3.8	3.5	10.3	3.9
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	3.5	4.9
balance-sheet.row.common-stock	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-713.95	-184.3	-168.5	-153.9	-95.4	-62.7	-47.5	-34	-22.9	-8.3	-2.4
balance-sheet.row.accumulated-other-comprehensive-income-loss	0	0	0	-1.2	-1.1	-1.3	-1.2	-1	-1.5	-1.3	-0.7
balance-sheet.row.other-total-stockholders-equity	724.43	187.9	171.3	147.3	93.8	68.6	53.1	36.6	27.6	2.5	0.9
balance-sheet.row.total-stockholders-equity	10.48	3.6	2.7	-7.8	-2.6	4.6	4.5	1.7	3.2	-3.6	2.6
balance-sheet.row.total-liabilities-and-stockholders-equity	22.67	6.9	5.4	11.8	12.9	8.9	7.5	5.5	6.8	6.7	6.6
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	10.48	3.6	2.7	-7.8	-2.6	4.6	4.5	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	22.67	-	-	-	-	-	-	-	-	-	-
Total Investments	0.09	0	0	0	0	0	0	0	7.9	0.1	0.1
balance-sheet.row.total-debt	2.1	0.8	0.9	1	0.6	1.6	0.3	0.4	0.2	6.6	1.1
balance-sheet.row.net-debt	-8.2	-2.9	-0.5	-7.2	-5.4	1.4	-0.9	-0.2	-1.6	6	1

现金流量表

在 First Wave BioPharma, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.424 的转变。该公司最近通过发行 15.83 扩大了股本，与上一年相比出现了56.000 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到-500000.000. 与上一年相比， 0.000 发生了变化. 在同一时期，公司记录了 0.03, 0 和 -0.6，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将-0.31 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 15.44，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016
cash-flows.row.net-income	-15.79	-15.8	-14.6	-58.5	-32.7	-15.2	-13.5	-11.1	-14.6	-5.9
cash-flows.row.depreciation-and-amortization	0.03	0	0	0.5	0.6	1	0.8	0.8	0.7	0.7
cash-flows.row.deferred-income-tax	-0.17	0.2	0	3.8	0.6	0	0.4	0	0	0
cash-flows.row.stock-based-compensation	1.04	1	0.8	1.4	0.5	1.2	2.5	0.6	0	0
cash-flows.row.change-in-working-capital	2.19	2.2	-10.5	17.1	14.2	-1.7	-1.7	-0.3	0.7	-0.7
cash-flows.row.account-receivables	0.09	0.1	-0.1	0.6	2.1	-0.7	0	0	0	0
cash-flows.row.inventory	0.75	0	0.1	-0.6	-2.1	0.7	0	0	0	0
cash-flows.row.account-payables	-0.17	-0.2	-2	1.4	-0.8	-0.4	0.7	-0.2	0.8	0
cash-flows.row.other-working-capital	1.51	2.3	-8.5	15.7	14.9	-1.3	-2.5	0	-0.1	-0.7
cash-flows.row.other-non-cash-items	0.32	0	2	3.5	5.6	0.6	0.7	2.8	8.6	1.4
cash-flows.row.net-cash-provided-by-operating-activities	-12.38	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-0.5	-0.5	0	-10.3	0	0	-0.1	0	0	0
cash-flows.row.acquisitions-net	0	0	0	0	0.1	0	0	0	0	0
cash-flows.row.purchases-of-investments	0	0	0	0	0	0	0	0	0	0
cash-flows.row.sales-maturities-of-investments	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-investing-activites	0	0	0	0	0	0	-0.3	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	-0.5	-0.5	0	-10.3	0.1	0	-0.3	0	0	0
cash-flows.row.debt-repayment	-0.6	-0.6	-0.6	-507125	-1.2	-1.9	-0.5	-0.3	-0.4	-0.8
cash-flows.row.common-stock-issued	9.88	15.8	23	32.7	1	9.5	2.3	5	5.3	0
cash-flows.row.common-stock-repurchased	0	0	0	4000000	8.2	1.7	0	0	0	0
cash-flows.row.dividends-paid	0	-0.3	0	-4507125	-8.2	-1.7	0	0	0	0
cash-flows.row.other-financing-activites	6.04	15.4	-6.6	1014262.1	17.2	5.5	9.9	1.3	0.9	5.8
cash-flows.row.net-cash-used-provided-by-financing-activities	15.23	15.2	15.7	44.8	17	13.1	11.7	6	5.7	5
cash-flows.row.effect-of-forex-changes-on-cash	0	0	-0.3	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	2.35	2.3	-6.9	2.2	5.9	-0.9	0.5	-1.2	1.2	0.5
cash-flows.row.cash-at-end-of-period	10.37	3.7	1.4	8.2	6.1	0.2	1.1	0.6	1.8	0.6
cash-flows.row.cash-at-beginning-of-period	8.02	1.4	8.2	6.1	0.2	1.1	0.6	1.8	0.6	0.1
cash-flows.row.operating-cash-flow	-12.38	-12.4	-22.3	-32.3	-11.2	-14	-10.9	-7.2	-4.5	-4.5
cash-flows.row.capital-expenditure	-0.5	-0.5	0	-10.3	0	0	-0.1	0	0	0
cash-flows.row.free-cash-flow	-12.88	-12.9	-22.3	-42.6	-11.2	-14.1	-10.9	-7.2	-4.5	-4.5

利润表行

First Wave BioPharma, Inc. 的收入与上期相比变化了 0.000%。据报告, FWBI 的毛利润为 -0.03。该公司的营业费用为 15.74，与上年相比变化了 24.164%. 折旧和摊销费用为 0.03，与上一会计期间相比变化了 -1.150%. 营业费用报告为 15.74，显示24.164% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长-0.244%. 营业收入为 -15.77，与上年相比变化了0.244%. 净利润的变化率为 -0.047%。去年的净收入为-15.79.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016
income-statement-row.row.total-revenue	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.cost-of-revenue	0.08	0	0.1	0.5	0.6	1	0	0	0	0
income-statement-row.row.gross-profit	-0.08	0	-0.1	-0.5	-0.6	-1	0	0	0	0
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	5.03	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	10.74	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	-0.01	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	0	0	-0.2	0.5	0.2	0	-0.2	0	0	0
income-statement-row.row.operating-expenses	15.76	15.7	12.7	56.7	26.4	14.7	13.4	10.1	6.6	4.7
income-statement-row.row.cost-and-expenses	15.77	15.8	12.7	56.7	26.4	14.7	13.4	10.1	6.6	4.7
income-statement-row.row.interest-income	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	0.02	0	0	0	5.8	0.4	0.1	0.9	5.9	1.6
income-statement-row.row.selling-and-marketing-expenses	-0.01	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-0.02	0	-2	0.5	-6.2	-0.4	-0.2	-0.1	-2	0.4
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	0	0	-0.2	0.5	0.2	0	-0.2	0	0	0
income-statement-row.row.total-operating-expenses	-0.02	0	-2	0.5	-6.2	-0.4	-0.2	-0.1	-2	0.4
income-statement-row.row.interest-expense	0.02	0	0	0	5.8	0.4	0.1	0.9	5.9	1.6
income-statement-row.row.depreciation-and-amortization	0.03	0	-0.2	3.4	0.8	1	0.8	0.8	0.7	0.7
income-statement-row.row.ebitda-caps	-15.74	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-15.77	-15.8	-12.7	-59.1	-26.4	-14.7	-13.4	-10.2	-6.3	-4.7
income-statement-row.row.income-before-tax	-15.79	-15.8	-14.6	-58.5	-32.7	-15.2	-13.5	-11.1	-14.6	-5.9
income-statement-row.row.income-tax-expense	0.02	0	2	0.5	6.1	0.4	-0.1	0.9	5.9	1.6
income-statement-row.row.net-income	-15.81	-15.8	-16.6	-59.1	-38.7	-15.6	-13.5	-11.1	-14.6	-5.9